pre-IPO PHARMA

COMPANY OVERVIEW

Apexian is a biotechnology company focused on developing novel compounds to treat cancer. Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others.


LOCATION

  • Indianapolis, IN, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://apexianpharma.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jan 22, 2020

    Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals


    Jul 2, 2019

    Apexian Pharmaceuticals' Clinical Candidate, APX3330, to Be Studied in Diabetic Models of Preleukemic Cells With Specific Mutations to Leukemia


    Dec 19, 2018

    Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia


    Dec 12, 2018

    Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia in Preclinical Models


    Dec 5, 2018

    Apexian Pharmaceuticals Presents Data on Their Lead Drug for Anti-Chemotherapy-Induced Peripheral Neuropathy (CIPN), APX3330, at ASCO Palliative Care and Symptom Management Meeting


    For More Press Releases


    Google Analytics Alternative